Latest / Breaking News To Trading Moves
The Merck-Terns Deal: Shaping the Future of Oncology M&A 1 source
Merck nears $6 billion deal for Terns Pharma: what it means for oncology stocks
Welcome to Breaking News to Trading Moves. Today’s big story is a healthcare deal headline that could ripple well beyond 2 stocks. Merck is nearing a roughly $6 billion all-cash acquisition of Terns Pharma; a move aimed at strengthening its cancer portfolio as it prepares for Keytruda’s patent expiry in 2028. Terns shares also jumped about 10% in after-hours trading on the news.
Why this matters for traders is simple. When a pharma giant starts paying up for oncology assets, the market often stops treating it as…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.